MGC Pharmaceuticals gives update on its drug for COVID-19 and post COVID-19 syndrome
LONDON: MGC Pharmaceuticals Ltd (ASX: MXC), a European based bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines, announced further results from the Phase II clinical and preclinical studies on ArtemiC, evaluating the efficacy on anti-inflammatory agents for…